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ABSTRACT The papillomavirus (PV) E2 protein is a sequence-specific DNA binding
protein that recruits cellular factors to its genome in infected epithelial cells. E2 also
binds to and loads the viral E1 DNA helicase at the origin of replication. Posttransla-
tional modifications (PTMs) of PV E2 have been identified as potential regulators of
E2 functions. We recently reported lysine 111 (K111) as a target of p300 acetylation
in bovine PV (BPV). The di-lysines at 111 and 112 are conserved in almost all papillo-
maviruses. We pursued a mutational approach to query the functional signifi-
cance of lysine in human PV (HPV) E2. Amino acid substitutions that prevent acety-
lation, including arginine, were unable to stimulate transcription and E1-mediated
DNA replication. The arginine K111 mutant retained E2 transcriptional repression,
nuclear localization, DNA and chromatin binding, and association with E2 binding
partners involved in PV transcription and replication. While the replication-defective
E2-K111R mutant recruited E1 to the viral replication origin, surprisingly, unwinding
of the duplex DNA did not occur. In contrast, the K111 glutamine (K111Q) mutant
increased origin melting and stimulated replication compared to wild-type E2. These
experiments reveal a novel activity of E2 necessary for denaturing the viral origin
that likely depends on acetylation of highly conserved lysine 111.
IMPORTANCE HPV is one of the most common sexually transmitted infections in
the United States. Over 200 HPVs have been described, and they manifest in a vari-
ety of ways; they can be asymptomatic or can result in benign lesions (papillomas)
or progress to malignancy. Although 90% of infections are asymptomatic and re-
solve easily, HPV16 and -18 alone are responsible for 70% of all cervical cancers,
which are almost entirely caused by HPV infection. Interestingly, 60 to 90% of other
cancers have been linked to HPV. The goal of this research is to further elucidate
the mechanisms that regulate and mediate viral replication.
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Papillomaviruses (PVs) are a family of nonenveloped DNA viruses that are the majoretiological agents of cervical and oropharyngeal cancers. The circular, double-
stranded DNA genome is approximately 8 kb and is comprised of a long control region
(LCR) (1) and eight open reading frames (2–5). The proteins expressed by the virus are
conserved in both structure and function across the various papillomaviruses (6). These
multifunctional proteins and splice variants regulate viral mechanisms and manipulate
infected cells directly and through interactions with host proteins.
The viral replicative program can be separated into three defined stages: establish-
ment, maintenance, and vegetative amplification (7). The initiation of a papillomavirus
infection results in the establishment and maintenance of a low copy number of
double-stranded viral episomes within infected basal keratinocytes. The papillomavirus
replicative program is closely linked to the life cycle of keratinocyte host cells and is
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moderated by a combination of viral and host cell factors. During establishment, there
is an initial amplification of replication to establish a low copy number of viral genomes
in basal cells. During the maintenance stage, low copy numbers of viral episomes are
maintained in the basal keratinocytes. This is followed by the vegetative amplification
stage in differentiating cells of the upper epithelial strata, where the viral copy number
is increased, late genes are expressed, and virions are packaged (3). There is a distinct
correlation between the differentiation of keratinocytes and the switch from the
maintenance to the amplification stage; however, the details of how the virus senses
and progresses through these stages and how replication is regulated remain un-
known.
The papillomavirus E2 protein is the major transcriptional regulator of viral gene
expression and a viral replication initiation protein (8–11). The structure of E2 consists
of an N-terminal transactivation domain (TAD) and a C-terminal DNA binding domain,
held together by an unstructured linker region. E2 regulates transcription by recruiting
factors to the viral genome that result in either the activation or repression of tran-
scription (12), through steric hindrance or by blocking the binding of host transcription
factors such as Sp1 and TATA binding protein (TBP) (1, 13, 14). These activities involve
the recruitment of certain host factors that are involved in chromatin processing such
as chromatin adaptor Brd4, AMF1/GPS2, Tip60 histone acetyltransferase (HAT) complex
subunit EP400, and the demethylase JARDIC/SMCX (15–19). Transcriptional repression
of E6 and E7 by E2 is important for the stable maintenance of the virus, and loss of
this function and subsequent increases in the levels of E6 and E7 may lead to the
progression of malignancy with high-risk papillomaviruses (20, 21).
Previous replication studies have identified the early proteins E1 and E2 as the only
viral proteins necessary for transient replication of the viral genome (22–24). E1 is the
major replication initiation protein and has both DNA binding and helicase activity but
does not demonstrate high specificity in DNA recognition. The papillomavirus replica-
tion origin contains E1 binding sites, which are flanked by high-affinity E2 binding sites.
E2 binds specifically to these sites at the origin and recruits E1 monomers. E2 is
displaced in an ATP-dependent process, and E1 forms a double hexameric helicase
complex that unwinds the DNA (25). Although the behavior of E1 and E2 during
replication initiation has been established (26, 27), the exact dynamics at the replication
origins and what host replication machinery is involved are still being investigated.
Higher levels of E2 protein are present in the upper layers of the epithelium, where
the virus enters the amplification stage of its replicative program (28). Recent reports
demonstrated that keratinocyte differentiation coincides with and is induced by ex-
pression of the acetyltransferase p300 (29). Posttranslational modifications (PTMs) that
affect papillomavirus E2 function have been previously identified. Phosphorylations in
the hinge region of bovine papillomavirus 1 (BPV1) E2 at serines 290, 298, and 301
result in higher copy numbers of viral genomes (30). We have identified conserved
lysine residues in BPV1 E2 that were acetylated by p300 in vitro and regulate its
transcriptional activation capability (31). These lysines at positions 111 and 112 (K111
and K112) are conserved in more than 90% of papillomaviruses, including BPV1 and
cancer-associated “high-risk” HPV16, -18, and -31. Here we examined the role of these
HPV31 E2 lysines in the initiation of DNA replication. We discovered that viral replica-
tion did not tolerate the conservative mutation of K111 to arginine (K111R). Unexpect-
edly, our data reveal that DNA unwinding by the E1 helicase depends on a PTM at lysine
111 in E2.
RESULTS
Mutation of K111 affects transient viral replication. Two lysine residues, K111
and K112, are very highly conserved among human and animal papillomaviruses (PVs)
(Fig. 1A). We previously demonstrated the requirement of lysine 111 for BPV1 E2
transcriptional activation (31). While E2 is known to bind and localize the E1 helicase to
high-affinity E2 binding sites at the viral origin, additional activities for E2 in DNA
replication have not been elucidated. We began testing both BPV and HPV31 E2 lysine
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111 and 112 mutants (E2-K111 and E2-K112) for stimulation of E1-dependent viral
replication by cotransfection with the corresponding E1 gene and the PV origin-
containing luciferase reporter construct. This di-lysine motif has been previously stud-
ied in BPV1, and mutations of each of these lysines resulted in decreased viral
replication, with K111R causing a more severe reduction (32, 33). Compared to wild-
type BPV E2, mutations of these lysines had deleterious effects on replication; K112R
resulted in a 3-fold reduction, and K111R completely abrogated transient DNA repli-
cation, similarly to the replication-dead W145R mutant (Fig. 1B). The conservative
arginine and alanine mutations were then tested in the context of HPV31 E2. The results
indicate that mutations that prevent acetylation at K111 or mimic a deacetylated
lysine—arginine and alanine, respectively—failed to induce E1-dependent replication
(Fig. 1C). However, the mutation of HPV31 K111 to glutamine (K111Q), which resembles
an acetylated lysine, stimulated replication to levels that surpassed wild-type E2. We
ensured that the abrogation of replication from the K111R mutant HPV31 E2 protein
was not due to reduced cell viability (Fig. 1C). These experiments also demonstrated
that while replication is affected by K112 in the context of BPV1 (31), mutations at this
position in HPV31 E2 did not exhibit a similar dependence (Fig. 1C).
An E2 mutation that reduces the interaction between E2 and E1 would likely alter
viral replication, so we investigated E1-E2 association to determine if that was affected
by the K111 mutations. Coimmunoprecipitation (co-IP) studies were conducted in
293TT cells that were cotransfected with hemagglutinin (HA)-tagged E1 and FLAG-
tagged E2. E1 immunoprecipitation (with HA7 antibody) and Western blot analysis
revealed that E1 interacted with both of the E2 mutants (Fig. 1D).
A possible explanation for this loss of activity is that K111 is located near the
putative nuclear localization signal (NLS) within the E2 TAD. Deletion mutations in this
FIG 1 K111 is necessary for transient viral replication. Mutations of E2 lysine 111 (K111) alter transient replication. (A) Sequence alignment shows the highly
conserved K111. (B) C33A cells were cotransfected with BPV1 E2-K111 mutants, pFLORI-BPV1, and pRRL and (C) C33A cells were cotransfected with HPV31
E2-K111 mutants. E2 mutants were cotransfected with pFLOri31. The luminescence was normalized to Renilla luciferase and the respective background E2
luminescence. Each of the samples was normalized to its respective control without E1 to cancel out any background effect. (Inset) The effect of K111R mutation
on cell viability and cell cycle was determined by flow cytometry. (D) 293TT cells were cotransfected with HPV31 FLAG-E2 and HA-E1. E1 protein pulldown was
conducted using 12CA5 antibody and blotted with HA7 and M2 antibodies. *, P  0.05; **, P  0.005.
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region of BPV1 were reported to cause E2 to be diffused throughout the cell rather than
nuclear (34). To determine if the mutants demonstrate the same effect in HPV31, we
used immunofluorescence to observe the location of E2 and investigate whether the
inability of the K111R mutant to initiate replication is due to the protein not being
present within the nucleus. In transfected C33A cells and cells of a line of spontaneously
immortalized keratinocytes (NIKs), E2 nuclear localization was unaffected by the K111
mutations (Fig. 2). These results clearly indicate that mutations at K111 do not inacti-
vate the putative NLS and K111R remains predominantly nuclear.
HPV31 E2 lysine 111 mutants repress transcription. Although K111 is located in
the transactivation domain of E2 and not the C-terminal DNA binding region, we still
investigated the ability of the mutants to recognize the E2 binding sites. Chromatin
immunoprecipitation (ChIP) was used to determine whether the DNA binding ability of
E2 was impaired in the K111R mutant (Fig. 3A). Both HPV31 E2-K111R and E2-K111Q
were able to bind near the origin using the HPV31 LCR4 primers, with no significant
differences compared to wild-type E2.
Due to the similar consequences of the K111 mutants on replication in BPV1 and
HPV31, we investigated the transcriptional activities of the K111 mutants. Unlike BPV E2
protein, which is a strong activator, the HPV31 E2 protein acts as an efficient repressor
of viral gene transcription (35–37). To examine the effects of mutating K111 on E2
transcriptional repression, we used the HPV31 promoter-luciferase assay (Fig. 3B). C33A
cells were transfected with plasmids expressing HPV31 E2 and a plasmid containing a
portion of the HPV31 LCR containing the E2 binding sites and p97 promoter upstream
of the firefly luciferase gene. Transfected amounts of wild-type E2 plasmid were first
titrated to validate the concentrations of E2 used for the assay. K111R, K111Q, and
K111A mutants repressed transcription at levels equivalent to those of wild-type E2
(Fig. 3B). This indicates that K111 is not necessary for HPV31 transcriptional repression.
This conclusion was confirmed by an assay for repression of E6 transcription in HeLa
cells. E2 represses transcription in the integrated HPV18 genomes present in these cells,
resulting in a reduction of E6 mRNA. HeLa cells were transfected with either a vector
control or HPV31 E2 plasmids. Compared to the negative control, HeLa cells transfected
with wild-type E2 as well as the E2 mutants showed diminished transcription of the E6
gene (Fig. 3C). Together with the ChIP results, these experiments confirm that the K111
mutants are able to access E2 binding sites in the context of chromatin.
HPV31 E2-K111 mutants maintain interactions with cellular factors. E2 interacts
with a large number of host factors, some of which have adverse impact on replication
when binding to E2 is abrogated. Brd4 is a cellular transcription factor that recognizes
acetyl-lysines. In the BPV1 system, interaction between E2 and Brd4 has been shown to
be critical for its transcriptional activation function. The HPV16 E2 Brd4 binding-
FIG 2 K111 is not required for nuclear localization of E2. C33A cells and NIKs were transfected with the
HPV31 E2 wild type (wt) and the K111 mutants. The cells were stained with HA7 48 h posttransfection
and analyzed by immunofluorescence for E2 (red) and DAPI (blue).
Thomas and Androphy Journal of Virology
February 2018 Volume 92 Issue 3 e01912-17 jvi.asm.org 4
deficient R37A I73A mutant is also defective in viral replication (38). Brd4 is known to
bind to the E2 N-terminal transcriptional activation domain and localizes to distinct foci
during the initiation of viral replication before being displaced from actively replicating
origins (38, 39). Three specific regions of Brd4 were reported to potentially interact with E2
(40, 41): the C-terminal motif (CTM), basic residue-enriched interaction domain (BID), and
phosphorylation-dependent interaction domain (PDID). The interaction of HPV31 E2 was
investigated by coimmunoprecipitation experiments with each of the Brd4 binding regions
(Fig. 4A). Neither E2-K111R nor E2-K111Q was found to be deficient for Brd4 binding.
FIG 3 HPV31 E2 lysine 111 (K111) mutations repress transcription. C33A cells were cotransfected with
31-Fluc and HPV31 FLAG-tagged E2 wild type (wt) or K111 mutants. The amount of E2 at the origin was
determined by ChIP using LCR4 primers (A). C33A cells were cotransfected with 31-Fluc and HPV31
FLAG-E2 wild type or K111 mutants. Repression was measured by luminometry and is shown as a fraction
of baseline transcription (B). HeLa cells were transfected with HPV31 HA-E2 wild type and harvested after
48 h, and E6 transcripts were quantified by qPCR (C). *, P  0.05.
Acetylation of a Conserved Lysine in HPV E2 Journal of Virology
February 2018 Volume 92 Issue 3 e01912-17 jvi.asm.org 5
The GPS2 (AMF1) protein is another factor known to interact with E2 proteins (16).
GPS2 is a positive regulator of E2 transcriptional activation in BPV1 (17). A binding-
deficient mutant of BPV1 E2, E2-W145R, is also transcription and replication defective
(16, 17). We investigated the interaction of the HPV31 E2 mutants with GPS2 by
coimmunoprecipitation and found that the K111 mutants interacted with GPS2 (Fig.
4B). Interestingly, we also found that the E2 mutants differentially affected the expres-
sion of GPS2 from the transfected plasmid. The relative interactions of the E2 proteins
and GPS2 were analyzed by densitometry, and we found that K111Q-transfected cells
showed higher levels of GPS2, while K111R cells exhibited reduced levels compared to
cells transfected with wild-type E2.
Topoisomerase II-binding protein 1 (TopBP1) is involved in DNA damage repair and
DNA replication (42). TopBP1 influences viral replication (43) and colocalizes with HPV
FIG 4 HPV31 E2-K111 mutants maintain interactions with cellular factors. (A) 293TT cells were cotransfected with HPV31 FLAG-E2, and plasmids expressing BRD4
fragments CTM, BID, and PDID. BRD4 proteins were pulled down using glutathione S-transferase (GST) antibody and blotted with GST and M2 antibodies. (B)
293TT cells were cotransfected with HPV31 FLAG-E2 and HA-GPS2. HPV31 E2 protein pulldown was executed with M2 antibody and blotted with HA7 and M2
antibodies. Relative GPS2 binding was calculated by densitometry and presented graphically. (C) 293TT cells were transfected with HPV31 FLAG-E2 followed
by E2 protein immunoprecipitation with M2 antibody. The amounts of endogenous TopBP1 coimmunoprecipitated were determined by blotting with
anti-TopBP1 and anti-M2 antibodies, and relative binding was calculated by densitometry and represented graphically.
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E2 at viral replication origins, proposed to occur as part of a DNA damage response (44,
45). TopBP1 complexes with HPV E2 and is important for establishing the copy number
of viral genomes (46), and it also increases replication and transcriptional activities of
E2. We found that both HPV31 E2-K111R and E2-K111Q maintained TopBP1 interaction
in a similar manner to the wild type (Fig. 4C). Blots were analyzed by densitometric
analysis to quantify the association of TopBP1 and the mutants relative to the wild type.
E1 protein complexes with and is recruited to the replication origin by E2-K111
mutants. During replication initiation, E2 binds and recruits E1 to the replication origin.
Although we have already established that the E2 mutants bind both DNA and E1, we
investigated the efficiency with which the K111 mutants translocated E1 to the viral
origin using ChIP assays. C33A cells were cotransfected with E1, E2, and PFLORI (Fig. 5B),
and HeLa cells were cotransfected with HPV31 E1 and E2 (Fig. 5B). We found that the
K111R and K111Q mutants both effectively recruited E1 to the viral replication origin in
both models.
The K111R mutant abrogates unwinding of the replication origin. These results
with the K111R E2 protein were intriguing. Our current understanding of HPV replica-
tion suggests that since the K111R mutant binds chromatin and recruits E1 to the
origin, replication initiation should be unaffected; however, that was not the case.
During initiation, the assembly of the E1 double hexamer follows the recruitment of
E1 to the origin by E2. To determine whether the E1 helicase was active, a FAIRE
(formaldehyde-assisted isolation of regulatory elements) assay was modified to infer
DNA unwinding at the replication origin. FAIRE assays are typically used to identify
FIG 5 E1 protein complexes with and is recruited to the replication origin by the E2-K111 mutants. (A)
C33A cells were cotransfected with PFLORI31, HPV31 HA-E2, and FLAG-E1. ChIP for E1 was conducted
with M2 antibody and LCR4 primers. (B) HeLa cells were transfected with HPV31 FLAG-E1 and HA-E2, and
the presence of E2 at the HeLa origin was determined by ChIP. *, P  0.05; **, P  0.005.
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active promoters by detecting sites in chromatin that are nucleosome free (47–49). This
principle was applied to investigate the viral replication origin. Compared to E1 alone, E1
cotransfected with the wild type resulted in 16-fold unwinding at the origin. The K111R
mutant yielded low levels of sheared origin DNA indicating that E1 helicase activity is
restricted by this mutation (Fig. 6A). The K111Q mutant also yielded interesting results as
it produced 21-foldmore naked origin DNA than E1 alone, which is significantly higher than
that produced by the wild type. These data imply that the E2-K111R change did not allow
unwinding of the replication origin while the K111Q mutation enhanced it.
We then corroborated the FAIRE results with a second assay. Replication protein A
(RPA) is a cellular factor that engages single-stranded DNA (ssDNA) at the viral origin
(50). We performed a ChIP assay for endogenous RPA (51) in cells cotransfected with
HPV31 E1 and E2 (Fig. 6B). In cells expressing E1 and E2-K111R, recruitment of RPA to
the HPV31 origin was not observed. Interestingly, the K111Q mutant showed an
3-fold increase in unwound DNA compared to the wild type. These results support
the findings of the FAIRE assay and demonstrate that both E1 and E2 are required for
the recruitment of RPA and that origin melting is the event in replication initiation that
is dependent upon acetylation of K111.
DISCUSSION
The role of papillomavirus E2 in replication initiation has been extensively studied;
however, the mechanisms by which replication and copy number are regulated and the
FIG 6 The K111R mutant reduces unwinding of the replication origin. C33A cells were transfected with
FLAG-E1, FLAG-E2, or PFLORI31. Unwinding at origin DNA was analyzed by FAIRE assay using HPV31 LCR
primers LCR3 and LCR4 (A). (B) ChIP for RPA protein at the LCR used anti-RPA70 antibody and LCR4
primers. *, P  0.05 by one-way ANOVA compared to the wild type in the absence of E1; #, P  0.05 by
one-way ANOVA compared to wild-type E2 plus E1.
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specific involvement of E2 beyond E1 recruitment remain undefined. Activation of the
early promoter (p97) leads to the expression of proteins E1, E2, E6, and E7 (9, 23, 33).
The E1 protein is the primary viral replication protein. It has been reported that in vitro,
E1 is capable of initiating viral replication from a histone-free template in the absence
of E2; however, the binding of E1 to DNA is relatively nonspecific and E2 is required in
vivo (50). For viral genome replication, E2 binds to DNA in a sequence-specific manner
at sites that form the origin of replication and recruits E1 monomers to its preferred
adjacent sites. After the first pair of E1 molecules arrives at the replication origin, E2 is
released from its binding sites through a process of ATP hydrolysis (52). More E1
molecules are recruited and form a double hexameric complex at the origin that is
similar to the eukaryotic ORC-MCM helicase. This E1 complex then acts as a helicase and
unwinds the DNA to allow cellular DNA polymerases and associated factors to be
recruited. Without E2 serving as a viral origin recognition factor, the inability of E1 to
bind specifically to the replication origin would cause inefficient and inconsistent firing.
Lysine acetylation is a reversible PTM that is essential for activation/deactivation of
many pathways; for example, the acetylation of histones by acetyl transferases is
necessary for transcriptional activation. We first identified this E2 lysine modification
through a p300 in vitro acetylation assay (31). It has been reported that p300 levels in
basal keratinocytes are very low, while differentiating cells show high levels (29). This
difference in p300 levels coincides with the switch of viral genomes from maintenance
to vegetative amplification in infected cells. To explore the importance of this acety-
lation, we designed mutants that represent deacetylated and acetylated K111 (K111R
and K111Q, respectively). The acetylation-deficient mutant E2-K111R was observed to
abrogate replication in both BPV1 (31) and HPV31, as reported here. As shown in Fig.
1C, the acetylation mimetic E2-K111Q demonstrated significantly higher levels of
replication than wild-type E2. This supports the hypothesis that acetylation at the 111
residue is a necessary step in the initiation of replication. Furthermore, the K111Q result
suggests that acetylation at K111 may be an integral regulatory step in switching the
viral replicative program from maintenance to vegetative amplification (53).
To determine how K111 affects replication, we further characterized the K111R and
K111Q mutants. Since K111 is located in the putative NLS, we investigated the
localization of E2 and found that like wild-type E2, the mutants were also nuclear (Fig.
2). Since the K111 mutations did not affect nuclear localization, we enquired whether
other functions of E2 were compromised. Knowing that a DNA-binding-deficient
mutant would be detrimental to viral replication, we conducted a ChIP assay of E2 at
the origin that allowed direct comparisons of the K111 mutants to wild-type E2. We
observed no differences among the E2 proteins bound to the viral replicon (Fig. 5),
confirming that the C-terminal DNA binding domain was not influenced by the K111
mutations. HPV31 E2 serves as a strong repressor of transcription, and according to our
results from two corroborating experiments (Fig. 3), this function is maintained at levels
similar to wild type for both mutants. The ability of HPV31 E2 to repress transcription
results from binding at sites located on the TATA box of the p97 promoter as well as
interaction with host cell transcription factors (1, 12, 54–56). The K111 mutants allow
transcriptional repression, which indirectly indicates that DNA binding and recruitment
of any essential cofactors are unaffected.
Several cellular factors that interact with E2 have been reported to directly affect E2
activities in viral transcription and genome replication. We investigated the ability of
the K111 mutants to interact with a subset of these proteins and found that the K111R
mutant was not binding deficient for any of them. An interesting observation was that
the E2 mutants exhibited differential expression levels (Fig. 4). The K111R mutant
showed lower expression than the wild type, and the K111Q mutant was expressed at
extremely low levels compared to the wild type or K111R mutant. Attempts to increase
the protein levels of the K111Q mutant by increasing the plasmid quantity transfected
as well as using proteasome inhibitor MG132 were ineffective. The coimmunoprecipi-
tation experiments with the fragments of BRD4 were an exception. The CTM of BRD4
stabilizes E2 (57), and that effect was clearly demonstrated, and the BID and PDID
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fragments also produced E2 stabilization to a lesser degree. While the expression of
K111Q was low, it remained highly active in all of the experiments, indicating that
despite low levels of expression, the acetylation mimic K111Q mutant is active and
results in enhanced viral replication.
K111 is located in the TAD, which is responsible for E1 binding (58). We found that
E1 binds to both K111 mutants, and the E2 mutants bound DNA and subsequently
recruited E1 to the replication origin at levels comparable to the wild type (Fig. 1D and
5). This interaction also demonstrates that the TAD of E2 is functional and therefore not
misfolded in the mutants. For the assembly of the E1 double hexamer helicase, E2
should not remain bound to E1 at the origin. One possible explanation for the lack of
replication is that the K111R mutant binds strongly to E1 and is unable to be released,
thereby hindering formation of the helicase complex and preventing unwinding at the
origin. We investigated the formation of the helicase complex by determining if the
origin becomes exposed under replication conditions by FAIRE assay. The FAIRE assay
was modified to measure the open chromatin at the origin under replication condi-
tions. Our results confirm that K111R is not capable of facilitating E1-dependent
unwinding of the replication origin (Fig. 6A).
To corroborate the results from the FAIRE assay, we performed a ChIP for RPA. Our
data reveal reduced RPA at the replication origin with K111R and a significant increase
with K111Q (Fig. 6B), consistent with a direct effect of E2 on the E1 recruitment of RPA
to the origin. Previous reports suggest that RPA is recruited to single-stranded DNA
(ssDNA) by interacting directly with E1 and this interaction is inhibited by ssDNA (50,
59). RPA was reported to interact with E2 using in vitro-expressed partially purified
proteins (60); however, this has not been established by in vivo coimmunoprecipitation,
and our attempts to visualize such an interaction have been unsuccessful. Since RPA is
necessary for DNA replication, it was proposed that E1 loads RPA onto ssDNA during
unwinding (50). The role of RPA in viral replication has been more extensively studied
in simian virus 40 (SV40). SV40 large T-antigen (TAg) has been reported to interact with
RPA, and during replication, the SV40 TAg-RPA interaction is essential for assembly of
the primosome (61). This specific function has not been determined for the E1-RPA
interaction, but a similar mechanism could explain how a lack of RPA loading at the
origin inhibits replication. Our data amend this proposed mechanism by adding the
requirement of E2 for the recruitment of RPA, since neither E1 nor E2 independently
recruited RPA to the origin (Fig. 6B).
This study characterized an acetylation site on HPV E2 that directly impacts viral
replication. Manipulation of K111 left the E2 localization, repression, DNA binding, and
E1 recruitment intact while only affecting viral replication. K111R was replication
defective, while the acetylation-mimetic K111Q enhanced viral replication, which lends
credence to the idea that it is an acetylation at this site that regulates viral replication.
We found that K111R abrogates replication by preventing the helicase activity of E1. It
is possible that E2 blocks the formation of the E1 helicase complex or that another
factor involved in episome unwinding is not recruited by the K111R mutant. Further
investigation of the interactions of HPV E2-K111 with factors directly involved in
replication initiation and DNA unwinding will be necessary to further our understand-
ing of how the K111 acetylation regulates replication mechanistically. An interesting
observation made here is that K111Q not only rescued the deficiencies of K111R, but
this mutant outperformed wild-type E2. We are currently studying K111 E2 mutants in
the context of the viral genome for establishment and replication in keratinocytes. This
possible acetylation presents a novel regulatory step in the PV replication program that
may be necessary for the transition from maintenance stage replication to vegetative
amplification.
MATERIALS AND METHODS
Cell culture, plasmids, and reagents. C33A and HeLa (ATCC), HEK 293TT (J. Schiller, C. Buck), and
J23T3 (H. Green) cells were maintained in Dulbecco’s modified Eagle’s medium (Life Technologies)
supplemented with 10% fetal bovine serum (FBS) (Atlas Biologicals) and 100 U/ml penicillin-streptomycin
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(Life Technologies). Cells of a spontaneously immortalized keratinocyte cell line (NIKs) were cocultured
in F medium (62) with mitomycin C-treated J23T3 cells.
C33A, and HeLa cells were transfected with Lipofectamine 2000. 293TT cells were transfected with 2
g/ml polyethylenimine (PEI) at a ratio of 1:2, and NIKs were transfected using X-tremeGene HP DNA
transfection reagent (Roche) at a ratio of 1:2 DNA to transfection reagent. HPV31 E2 mutant plasmids
were constructed by site-directed mutagenesis (Agilent; Quick-Change II) and verified by sequencing of
the entire E2 gene. HA-tagged HPV31 E2 was obtained from P. Howley (63), codon-optimized FLAG
HPV31 E2 was supplied by A. McBride (64), and the HPV31 E1, pCI-RLuc, and PFLORI31 constructs were
obtained from J. Archambault (65). Codon-optimized HA-31E1 was cloned into the NheI and ApaI sites
of PCDNA3.
Antibodies. Antibodies used include anti-TopBP1 (Bethyl), mouse anti-FLAG M2 (Sigma-Aldrich), and
mouse anti-HA (HA7; Sigma-Aldrich, 12CA5). Anti-RPA70 antibody (Abcam), goat anti-mouse 594, and
goat anti-rabbit 488-horseradish peroxidase (HRP) (Jackson ImmunoResearch) and Alexa Fluor (Thermo
Fisher) antibodies were purchased from commercial sources. Glutathione- and M2-conjugated beads
were obtained from Sigma-Aldrich.
Viral replication assay. The luciferase-based replication assay was performed as previously reported
(65). Ten nanograms each of BPV1/HPV31 E1, E2, and PFLORI31 constructs was cotransfected into C33A
cells in a 96-well plate. The pCI-RLuc construct (2.5 ng) was included to normalize for transcriptional
activation and transfection efficiency. Cells were incubated in transfection medium overnight, and the
medium was replaced. Seventy-two hours posttransfection, cells were lysed in Dual-Glo luciferase
reagent (Promega), and both firefly and Renilla luciferase levels were determined by luminometry on a
PHERAStar FS (BMG Labtech).
Flow cytometry. C33A cells at 50% confluence were transfected with 2 g of HPV31 HA-E2 in 60-cm
dishes. Forty-eight hours after transfection, the cells were harvested with 0.1% trypsin-EDTA, spun down,
and fixed in 90% ethanol. The samples were washed in PBS and treated with 50 g/l each of propidium
iodide and RNase A for 20 min. The samples were analyzed using a FACSCalibur instrument and the
FlowJo program.
Immunofluorescence. C33A cells and NIKs grown on coverslips were transfected with 2.5 ng of the
indicated HPV31 E2 plasmid. Cells were fixed 48 h posttransfection for 15 min in 4% formaldehyde
solution in PBS, washed three times with PBS, and permeabilized in PBT (0.2% Triton X–PBS) for 10 min.
The cells were blocked for 1 h in 10% normal goat serum–PBT and incubated with HA7 primary antibody
(1:5,000 in 10% normal goat serum–PBT) overnight. The cells were washed, incubated with secondary
antibodies (1:5,000 in 10% normal goat serum–PBT) for 1 h, and mounted with Vectashield antifade
mounting medium with DAPI (4=,6-diamidino-2-phenylindole [Vector Laboratories]). Cells were analyzed
using a Nikon microscope and QCapture Pro software.
Transcriptional repression luciferase assay. Twenty-five nanograms of HPV31 HA-E2 (WT or
mutant) or empty vector control (pCI) and 100 ng of HPV31-luc constructs were cotransfected into C33A
cells in each well of a 12-well plate. Forty-eight hours posttransfection, cells were lysed and processed
with the Dual-Glo luciferase kit (Promega). Luminescence was measured using the PHERAStar FS (BMG
Labtech).
HeLa repression assay. HeLa cells in 6-well dishes were transfected at 50% confluence with 1 g
HPV31 HA-E2 (WT or mutants). Forty-eight hours posttransfection, the cells were rinsed with cold PBS and
lysed directly in plates using 1 ml TRIzol. The cells were collected by scraping and homogenized by
several passes through an 18-gauge syringe. RNA was isolated by phase separation and resuspended in
diethyl pyrocarbonate (DEPC)-treated water. cDNA synthesis was conducted with the SuperScript III
first-strand synthesis system (Thermo Fisher Scientific), and cDNA was analyzed by quantitative PCR using
the following HPV18 E6 and actin primers: SKH 18E6 F01 (5=-GGTGCCAGAAACCGTTGAAT-3=) and SKH
18E6 R01 (5=-CGAATGGCACTGGCCTCTAT-3=) and HeLabActin F01 (5=-GGACATCCGCAAAGACCTGT-3=)
and HeLabActin R01 (5=-CCAGGGCAGTGATCTCCTTC-3=).
Coimmunoprecipitation and chromatin immunoprecipitation. 293TT cells were cotransfected
with plasmids expressing a codon-optimized FLAG-tagged HPV31 E2 and the protein of interest. The cells
were harvested 48 h posttransfection and lysed in 1 ml NP-40 buffer (0.5% NP-40, 50 mM Tris, 150 M
NaCl) for 10 min on ice. One hundred units of Benzonase endonuclease was added to each sample for
30 min. Samples were centrifuged, and supernatants were collected in fresh tubes for immunoprecipi-
tations and inputs. For co-IP, the samples were rotated overnight at 4°C with either antibody-conjugated
beads (glutathione or M2), or Sepharose A/G beads and 1 g of antibody. The beads were washed five
times with NP-40 lysis buffer, resuspended, and boiled in SDS sample buffer. The samples and their
respective inputs were then analyzed by Western blotting.
For ChIP, C33A cells were transfected with plasmids (1:1:1) expressing HPV31 E1, E2 and the HPV31
origin of replication (PFLORI). Forty-eight hours posttransfection, the cells were cross-linked in 1%
paraformaldehyde for 10 min at room temperature. The cells were rinsed with cold PBS after the
cross-linking was stopped by addition of 0.125 M glycine, and then the cells were collected by scraping.
These samples were processed using the ChIP-It enzymatic shearing kit (Active Motif). The DNA from the
immunoprecipitations and their inputs were analyzed by quantitative PCR using primer pairs designed
against the HPV18 or -31 LCR.
FAIRE assay. Plasmids expressing HPV31 E2 and E1, along with a plasmid containing the LCR of
HPV31 (PFLORI), were transfected into C33A cells. Cells were harvested 48 h posttransfection. One
replicate of each sample was harvested immediately by scraping into cold PBS, and the other was
formaldehyde cross-linked with 1% paraformaldehyde for 10 min at room temperature. The cross-linking
was stopped with 0.125 M glycine for 1 min, and after washing with cold PBS, the samples were collected
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by scraping. After shearing with the ChIP-It enzymatic shearing kit (Active Motif), the chromatin was
extracted by phenol-chloroform extraction followed by ethanol precipitation and resuspended in
Tris-EDTA (TE) buffer. The cross-linked and respective uncross-linked control samples were analyzed by
quantitative PCR with primer sets designed for the HPV31 replication origin (66) LCR4: LCR3 F (5=-GTT
CTGCGGTTTTTGGTTTC-3=) and LCR3 R (5=-TGTTGGCAAGGTGTGTTAGG-3=) and LCR4 F (5=-AAAGTGGTGA
ACCGAAAACG-3=) and LCR4 R (5=-CATGCAATTTCCGAGGTCTT-3=).
Statistical analyses. Mean values are reported  the standard error of the mean (SEM). Two-way t
tests and one-way analysis of variance (ANOVA) were used for analyses (*, P  0.05).
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